This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neurology	Adenylate cyclase activating polypeptide pituitary (ADCYAP1; PACAP); ADCYAP1 receptor type 1 (ADCYAP1R1; PAC1)	<p>SAR analysis and <i>in vitro</i> studies suggest that a series of PACAP analogs could help treat stroke, neurotoxicity and other neurological conditions. The studies identified analogs of the 38-residue PACAP isoform that agonized PAC1. Also, an analog of the 27-residue isoform antagonized PAC1. Next steps could include using the analogs to guide the design of nonpeptidic agonists and antagonists of PAC1.</p> <p>SciBX 2(20); doi:10.1038/scibx.2009.840 Published online May 21, 2009</p>	Patent and licensing status unavailable	<p>Bourgault, S. <i>et al. J. Med. Chem.</i>; published online May 4, 2009; doi:10.1021/jm900291j</p> <p>Contact: Alain Fournier, Armand-Frappier Institute, National Institute for Scientific Research, Laval, Quebec, Canada e-mail: alain.fournier@iaf.inrs.ca</p>